Magazine Article | March 7, 2018

Companies To Watch: AmpliPhi Biosciences

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Pushing bacteriophage therapy development for drug-resistant infections — not to replace, but possibly to augment antibiotics.

AmpliPhi is developing bacteriophage (bacteria- killing viruses) as a new class of antibacterials. It has completed Phase 1 studies of a threephage product, coded AB-SA01, for treating multi-drug resistant (MDR) S. aureus infections, and a four-phage product, coded AB-PA01, is in preclinicals for treatment of P. aeruginosa infections, including MDR strains.